Short Summary
Geneoscopy challenges Exact Sciences' '781 patent on grounds of obviousness (103) related to colorectal cancer diagnostics. The petitioner argues that combining known methods for fecal sample processing, such as DNA methylation and blood protein testing, renders the claims unpatentable over prior art references. This challenge targets multiple diagnostic claim sets across the patent.
Detailed Summary
Geneoscopy, Inc. has filed a Petition challenging the validity of Exact Sciences Corporation's U.S. Patent No. 11634781 before the PTAB. The petitioner asserts that numerous claims are obvious under 35 U.S.C. § 103 because they merely combine well-established diagnostic techniques found in the prior art. Specifically, the challenge focuses on the combination of fecal DNA methylation assays (Lenhard) with blood protein detection methods (Vilkin), further supported by references detailing sample stabilization and collection improvements (Itzkowitz, Kanaoka, Derks). The petition covers a broad range of claims related to colorectal cancer diagnostics, asserting that the claimed inventive steps are routine optimizations in the field.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Geneoscopy, Inc. vs Exact Sciences Corporation is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Apple Inc.vsAdvanced Coding Technologies LLC
Apple has filed an IPR petition seeking to invalidate claims 1‑10 of U.S. Patent 8,090,025, asserting that the claims are obvious over a combination of prior‑art video‑coding references. The petition relies on Mualla, Shirani, Saito, Stockhammer, and Shimizu to demonstrate lack of novelty under 35 U.S.C. §103.
Vicor CorporationvsDelta Electronics, Inc.
Vicor Corporation challenged Delta Electronics' patent (8711580) in the PTAB, arguing that the resonant converter technology is obvious based on prior art publications. The petitioner successfully secured institution under §325(d) and §314(a), advancing its challenge to the Patent Owner.
RegenX Science Inc.vsNeXtGen Biologics, Inc.
Bankruptcy court approved a settlement between ISE and Synogen parties, including patent assignments and cash payments, leading to dismissal of related disputes.
Albany International Corp.vsVoith Patent GmbH
The PTAB granted institution for IPR2025-01367, allowing Albany International Corp. to challenge Voith Patent GmbH's patent 9982388.
Apple Inc.vsHBCU Messaging US LP
The PTAB instituted an inter partes review of Apple’s challenge to the ’077 patent, finding a reasonable likelihood of success on obviousness grounds over Bharadwaj and Yu references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.